The Global Fund is expanding its campaign to improve access to lenacapavir, an HIV prevention medicine given two times a year. The target is now to reach 3 million people by 2028, instead of the earlier goal of 2 million. Nine African countries have already received supplies, with plans to send more to twelve additional countries soon.

Lenacapavir is popular because it does not require daily pills. This makes it useful for people with limited healthcare access or busy lives. Early demand is high, especially among pregnant women, young women, and first-time users of HIV prevention medicine.

The expansion also aims to reduce the time it takes for new medicines to become available in poorer countries. The next steps depend on increasing the supply and making the medicine affordable. Generic production could help lower costs and help more people receive protection in the future.